On December 13, 2016 Invenra, Inc., a pre-clinical stage bio-pharmaceutical company focused on next-generation therapeutic human antibodies, bispecifics and antibody derivatives, and AgonOx, a biotechnology company developing a pipeline of immunotherapy drugs targeting key regulators of the immune response to cancer, reported a collaboration to identify and characterize a panel of fully human therapeutic monoclonal antibodies (mAbs) against a novel immuno-oncology target that AgonOx has identified utilizing its discovery platform (Press release, Invenra, DEC 13, 2016, View Source [SID1234539840]). Financial details of the deal were not disclosed.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Invenra’s proprietary platform is based on ultra-high throughput technology allowing function forward screening of full-length antibodies using Invenra’s mAbSeq technology, where antibodies can be directly and quickly interrogated in a multi-plexed fashion with a diverse set of immunotypic and biologically relevant assays. The Invenra technology allows rapid identification of high affinity mAbs with the broadest epitope coverage possible while simultaneously performing direct phenotypic screening to isolate those mAbs with the most relevant biological activity, thus leading to the election of the best lead compounds for further development.
AgonOx’s approach to target discovery begins with genomic and proteomic analyses of tumor-
infiltrating lymphocytes isolated from human tumor biopsies. Candidates identified by these analyses are further validated using in-vitro assays and predictive in vivo murine cancer models. Andrew Weinberg, President of AgonOx, said "Collaborating with Invenra strengthens our efforts to develop immuno-oncology drug candidates through their novel antibody platform and complements our mission of discovering and delivering science that can change the standard of care for patients with cancer. Invenra has first-rate scientists that we hope to work with for years to come."
Roland Green, CEO and president of Invenra, said, "This collaboration is a major milestone for Invenra as a company and a validation of our innovative technology. We are delighted to be collaborating with the excellent team at AgonOx to identify best-in-class antibodies against their novel immuno-oncology target. In addition, this collaboration with AgonOx fits well within our business model, whereby we are partnering with a select group of companies while continuing to develop our own internal proprietary pipeline of therapeutic product candidates."